UNSPSC 51183307: Saxagliptin hydrochloride

This classification denotes a protease inhibitor and anti-diabetic agent with the molecular formula C18H25N3O2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z8J84YIX6L. European Medicines Agency schedules saxagliptin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30804. The term saxagliptin hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule saxagliptin hydrochloride under HS 29339990 and SITC 51577.

As of Q4 2014, SAXAGLIPTIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Saxagliptin hydrochloride bears US NLM identifiers UMLS ID C2719771 and NCI Concept Code C81702. SMILES: C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H]([C@]34C[C@@H]5CC(C3)C[C@@](C5)(C4)O)N.CL.

UNSPSC 51183307 Saxagliptin hydrochloride is a Commodity code encompassing a specific active pharmaceutical ingredient — saxagliptin hydrochloride, a DPP-4 inhibitor for type 2 diabetes management — that state and local governments procure through cooperative purchasing vehicles and multistate pharmaceutical contracts. State and local health agencies, correctional facilities, public hospitals, and municipal health departments source this drug as part of broader generic pharmaceutical procurement programs. The recent MMCAP solicitation demonstrates the dominant procurement model: state and local buyers do not typically purchase individual active ingredients in bulk; instead, they contract with pharmaceutical manufacturers and wholesalers for finished generic products available through authorized distributors, with pricing negotiated at the wholesale or finished-product level rather than at the raw-ingredient stage. Saxagliptin hydrochloride appears in state and local procurement primarily as a finished-product component of multi-source generic pharmaceutical agreements rather than as a standalone active pharmaceutical ingredient.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon. The MMCAP RFP requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with awarded pricing and product information effective July 1, 2026, pending product availability by May 15, 2026. Evaluation prioritizes price competitiveness (75 percent weight), followed by fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must maintain commercial general liability of $5,000,000 per occurrence, comply with cGMP and DSCSA requirements, hold contractual relationships with at least two of the three authorized wholesalers, and demonstrate flexible pricing structures including flat price, net price formats, and WAC-minus options. The contract term is two years for new responders with optional extensions at MMCAP's discretion.